Yazhen Qin, Jin Lu, L. Bao, Honghu Zhu, Jin-lan Li, Ling-di Li, Y. Lai, Hong-xia Shi, Ya-zhe Wang, Yan-rong Liu, B. Jiang, Xiaojun Huang
{"title":"Bortezomib improves progression‐free survival in multiple myeloma patients overexpressing preferentially expressed antigen of melanoma","authors":"Yazhen Qin, Jin Lu, L. Bao, Honghu Zhu, Jin-lan Li, Ling-di Li, Y. Lai, Hong-xia Shi, Ya-zhe Wang, Yan-rong Liu, B. Jiang, Xiaojun Huang","doi":"10.3760/cma.j.issn.0366-6999.20132356","DOIUrl":null,"url":null,"abstract":"Background Significant efforts have been made to identify factors that differentiate patients treated with novel therapies, such as bortezomib in multiple myeloma (MM). The exact expression pattern and prognostic value of the cancer/testis antigen preferentially expressed antigen of melanoma (PRAME) in MM are unknown and were explored in this study. Methods The transcript level of PRAME was detected in bone marrow specimens from 100 newly diagnosed MM patients using real‐time quantitative polymerase chain reaction, and the prognostic value of PRAME was determined through retrospective survival analysis. PRAME expression higher than the upper limit of normal bone marrow was defined as PRAME overexpression or PRAME (+). Results Sixty‐two patients (62.0%) overexpressed PRAME. PRAME overexpression showed no prognostic significance to either overall survival (n=100) or progression‐free survival (PFS, n=96, all P >0.05) of patients. The patients were also categorized according to regimens with or without bortezomib. PRAME overexpression tended to be associated with a lower two‐year PFS rate in patients treated with non‐bortezomib‐containing regimens (53.5% vs. 76.9%, P=0.071). By contrast, it was not associated with the two‐year PFS rate in patients with bortezomib‐containing regimens (77.5% vs. 63.9%, P >0.05). When the patients were categorized into PRAME (+) and PRAME (‐) groups, treatment with bortezomib‐containing regimens predicted a higher two‐year PFS rate in PRAME (+) patients (77.5% vs. 53.5%, P=0.027) but showed no significant effect on two‐year PFS rate in PRAME (‐) patients (63.9% vs. 76.9%, P >0.05). Conclusion PRAME overexpression might be an adverse prognostic factor of PFS in MM patients treated with non‐bortezomib‐containing regimens. Bortezomib improves PFS in patients overexpressing PRAME.","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":null,"pages":null},"PeriodicalIF":7.5000,"publicationDate":"2014-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Medical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.issn.0366-6999.20132356","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 11
Abstract
Background Significant efforts have been made to identify factors that differentiate patients treated with novel therapies, such as bortezomib in multiple myeloma (MM). The exact expression pattern and prognostic value of the cancer/testis antigen preferentially expressed antigen of melanoma (PRAME) in MM are unknown and were explored in this study. Methods The transcript level of PRAME was detected in bone marrow specimens from 100 newly diagnosed MM patients using real‐time quantitative polymerase chain reaction, and the prognostic value of PRAME was determined through retrospective survival analysis. PRAME expression higher than the upper limit of normal bone marrow was defined as PRAME overexpression or PRAME (+). Results Sixty‐two patients (62.0%) overexpressed PRAME. PRAME overexpression showed no prognostic significance to either overall survival (n=100) or progression‐free survival (PFS, n=96, all P >0.05) of patients. The patients were also categorized according to regimens with or without bortezomib. PRAME overexpression tended to be associated with a lower two‐year PFS rate in patients treated with non‐bortezomib‐containing regimens (53.5% vs. 76.9%, P=0.071). By contrast, it was not associated with the two‐year PFS rate in patients with bortezomib‐containing regimens (77.5% vs. 63.9%, P >0.05). When the patients were categorized into PRAME (+) and PRAME (‐) groups, treatment with bortezomib‐containing regimens predicted a higher two‐year PFS rate in PRAME (+) patients (77.5% vs. 53.5%, P=0.027) but showed no significant effect on two‐year PFS rate in PRAME (‐) patients (63.9% vs. 76.9%, P >0.05). Conclusion PRAME overexpression might be an adverse prognostic factor of PFS in MM patients treated with non‐bortezomib‐containing regimens. Bortezomib improves PFS in patients overexpressing PRAME.
期刊介绍:
The Chinese Medical Journal (CMJ) is published semimonthly in English by the Chinese Medical Association, and is a peer reviewed general medical journal for all doctors, researchers, and health workers regardless of their medical specialty or type of employment. Established in 1887, it is the oldest medical periodical in China and is distributed worldwide. The journal functions as a window into China’s medical sciences and reflects the advances and progress in China’s medical sciences and technology. It serves the objective of international academic exchange. The journal includes Original Articles, Editorial, Review Articles, Medical Progress, Brief Reports, Case Reports, Viewpoint, Clinical Exchange, Letter,and News,etc. CMJ is abstracted or indexed in many databases including Biological Abstracts, Chemical Abstracts, Index Medicus/Medline, Science Citation Index (SCI), Current Contents, Cancerlit, Health Plan & Administration, Embase, Social Scisearch, Aidsline, Toxline, Biocommercial Abstracts, Arts and Humanities Search, Nuclear Science Abstracts, Water Resources Abstracts, Cab Abstracts, Occupation Safety & Health, etc. In 2007, the impact factor of the journal by SCI is 0.636, and the total citation is 2315.